Cargando…

Serum vascular endothelial growth factor is associated with cardiovascular involvement and response to therapy in Erdheim-Chester disease

Erdheim-Chester disease (ECD) is a rare histiocytosis, considered to be an inflammatory myeloid neoplasm. Tropism for specific involvements of the disease remains unexplained. Vascular endothelial growth factor-A (VEGF) is implicated in cancer pathophysiology and mutations of the RAS oncogene have b...

Descripción completa

Detalles Bibliográficos
Autores principales: Roeser, Anaïs, Bravetti, Marine, Dong, Lida, Azoulay, Levi-Dan, Charlotte, Frederic, Miyara, Makoto, Ghillani-Dalbin, Pascale, Emile, Jean-François, El Kouari, Fadwa, Ouni, Hamza, Lacorte, Jean-Marc, Brocheriou, Isabelle, Amoura, Zahir, Cohen-Aubart, Fleur, Haroche, Julien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890031/
https://www.ncbi.nlm.nih.gov/pubmed/36005561
http://dx.doi.org/10.3324/haematol.2022.280755
_version_ 1784880865254309888
author Roeser, Anaïs
Bravetti, Marine
Dong, Lida
Azoulay, Levi-Dan
Charlotte, Frederic
Miyara, Makoto
Ghillani-Dalbin, Pascale
Emile, Jean-François
El Kouari, Fadwa
Ouni, Hamza
Lacorte, Jean-Marc
Brocheriou, Isabelle
Amoura, Zahir
Cohen-Aubart, Fleur
Haroche, Julien
author_facet Roeser, Anaïs
Bravetti, Marine
Dong, Lida
Azoulay, Levi-Dan
Charlotte, Frederic
Miyara, Makoto
Ghillani-Dalbin, Pascale
Emile, Jean-François
El Kouari, Fadwa
Ouni, Hamza
Lacorte, Jean-Marc
Brocheriou, Isabelle
Amoura, Zahir
Cohen-Aubart, Fleur
Haroche, Julien
author_sort Roeser, Anaïs
collection PubMed
description Erdheim-Chester disease (ECD) is a rare histiocytosis, considered to be an inflammatory myeloid neoplasm. Tropism for specific involvements of the disease remains unexplained. Vascular endothelial growth factor-A (VEGF) is implicated in cancer pathophysiology and mutations of the RAS oncogene have been shown to induce upregulation of VEGF gene expression. We therefore hypothesized that VEGF might play a particular role in ECD pathophysiology. We conducted a retrospective, single-center study to assess serum VEGF (sVEGF) concentrations and determine whether they were associated with the characteristics of ECD patients, and to determine whether VEGF was expressed by histiocytes. We evaluated 247 ECD patients, 53.4% of whom had sVEGF levels above the normal range (>500 pg/mL). Patients with high sVEGF levels more frequently had cardiac and vascular involvement (58.3% vs. 41.4%, P=0.008 and 70.5% vs. 48.3%, P=0.0004, respectively). In treatment-naïve patients (n=135), the association of C-reactive protein >5 mg/L and sVEGF >500 pg/mL was strongly associated with vascular involvement (odds ratio=5.54 [95% confidence interval: 2.39-13.62], P<0.001), and independently associated with cardiac involvement (odds ratio=3.18 [95% confidence interval: 1.34-7.83], P=0.010) after adjustment for the presence of the BRAF V600E mutation. Changes in sVEGF concentration on treatment were associated with a response of cardiac involvement on consecutive cardiac magnetic resonance images. All histological samples analyzed (n=24) displayed histiocytes with intracytoplasmic expression of VEGF, which was moderate to high in more than 90% of cases. Our study suggests a role for VEGF in cardiac and vascular involvement in ECD.
format Online
Article
Text
id pubmed-9890031
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Fondazione Ferrata Storti
record_format MEDLINE/PubMed
spelling pubmed-98900312023-02-13 Serum vascular endothelial growth factor is associated with cardiovascular involvement and response to therapy in Erdheim-Chester disease Roeser, Anaïs Bravetti, Marine Dong, Lida Azoulay, Levi-Dan Charlotte, Frederic Miyara, Makoto Ghillani-Dalbin, Pascale Emile, Jean-François El Kouari, Fadwa Ouni, Hamza Lacorte, Jean-Marc Brocheriou, Isabelle Amoura, Zahir Cohen-Aubart, Fleur Haroche, Julien Haematologica Article - Inflammatory Myeloid Neoplasm Erdheim-Chester disease (ECD) is a rare histiocytosis, considered to be an inflammatory myeloid neoplasm. Tropism for specific involvements of the disease remains unexplained. Vascular endothelial growth factor-A (VEGF) is implicated in cancer pathophysiology and mutations of the RAS oncogene have been shown to induce upregulation of VEGF gene expression. We therefore hypothesized that VEGF might play a particular role in ECD pathophysiology. We conducted a retrospective, single-center study to assess serum VEGF (sVEGF) concentrations and determine whether they were associated with the characteristics of ECD patients, and to determine whether VEGF was expressed by histiocytes. We evaluated 247 ECD patients, 53.4% of whom had sVEGF levels above the normal range (>500 pg/mL). Patients with high sVEGF levels more frequently had cardiac and vascular involvement (58.3% vs. 41.4%, P=0.008 and 70.5% vs. 48.3%, P=0.0004, respectively). In treatment-naïve patients (n=135), the association of C-reactive protein >5 mg/L and sVEGF >500 pg/mL was strongly associated with vascular involvement (odds ratio=5.54 [95% confidence interval: 2.39-13.62], P<0.001), and independently associated with cardiac involvement (odds ratio=3.18 [95% confidence interval: 1.34-7.83], P=0.010) after adjustment for the presence of the BRAF V600E mutation. Changes in sVEGF concentration on treatment were associated with a response of cardiac involvement on consecutive cardiac magnetic resonance images. All histological samples analyzed (n=24) displayed histiocytes with intracytoplasmic expression of VEGF, which was moderate to high in more than 90% of cases. Our study suggests a role for VEGF in cardiac and vascular involvement in ECD. Fondazione Ferrata Storti 2022-08-25 /pmc/articles/PMC9890031/ /pubmed/36005561 http://dx.doi.org/10.3324/haematol.2022.280755 Text en Copyright© 2023 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Article - Inflammatory Myeloid Neoplasm
Roeser, Anaïs
Bravetti, Marine
Dong, Lida
Azoulay, Levi-Dan
Charlotte, Frederic
Miyara, Makoto
Ghillani-Dalbin, Pascale
Emile, Jean-François
El Kouari, Fadwa
Ouni, Hamza
Lacorte, Jean-Marc
Brocheriou, Isabelle
Amoura, Zahir
Cohen-Aubart, Fleur
Haroche, Julien
Serum vascular endothelial growth factor is associated with cardiovascular involvement and response to therapy in Erdheim-Chester disease
title Serum vascular endothelial growth factor is associated with cardiovascular involvement and response to therapy in Erdheim-Chester disease
title_full Serum vascular endothelial growth factor is associated with cardiovascular involvement and response to therapy in Erdheim-Chester disease
title_fullStr Serum vascular endothelial growth factor is associated with cardiovascular involvement and response to therapy in Erdheim-Chester disease
title_full_unstemmed Serum vascular endothelial growth factor is associated with cardiovascular involvement and response to therapy in Erdheim-Chester disease
title_short Serum vascular endothelial growth factor is associated with cardiovascular involvement and response to therapy in Erdheim-Chester disease
title_sort serum vascular endothelial growth factor is associated with cardiovascular involvement and response to therapy in erdheim-chester disease
topic Article - Inflammatory Myeloid Neoplasm
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890031/
https://www.ncbi.nlm.nih.gov/pubmed/36005561
http://dx.doi.org/10.3324/haematol.2022.280755
work_keys_str_mv AT roeseranais serumvascularendothelialgrowthfactorisassociatedwithcardiovascularinvolvementandresponsetotherapyinerdheimchesterdisease
AT bravettimarine serumvascularendothelialgrowthfactorisassociatedwithcardiovascularinvolvementandresponsetotherapyinerdheimchesterdisease
AT donglida serumvascularendothelialgrowthfactorisassociatedwithcardiovascularinvolvementandresponsetotherapyinerdheimchesterdisease
AT azoulaylevidan serumvascularendothelialgrowthfactorisassociatedwithcardiovascularinvolvementandresponsetotherapyinerdheimchesterdisease
AT charlottefrederic serumvascularendothelialgrowthfactorisassociatedwithcardiovascularinvolvementandresponsetotherapyinerdheimchesterdisease
AT miyaramakoto serumvascularendothelialgrowthfactorisassociatedwithcardiovascularinvolvementandresponsetotherapyinerdheimchesterdisease
AT ghillanidalbinpascale serumvascularendothelialgrowthfactorisassociatedwithcardiovascularinvolvementandresponsetotherapyinerdheimchesterdisease
AT emilejeanfrancois serumvascularendothelialgrowthfactorisassociatedwithcardiovascularinvolvementandresponsetotherapyinerdheimchesterdisease
AT elkouarifadwa serumvascularendothelialgrowthfactorisassociatedwithcardiovascularinvolvementandresponsetotherapyinerdheimchesterdisease
AT ounihamza serumvascularendothelialgrowthfactorisassociatedwithcardiovascularinvolvementandresponsetotherapyinerdheimchesterdisease
AT lacortejeanmarc serumvascularendothelialgrowthfactorisassociatedwithcardiovascularinvolvementandresponsetotherapyinerdheimchesterdisease
AT brocheriouisabelle serumvascularendothelialgrowthfactorisassociatedwithcardiovascularinvolvementandresponsetotherapyinerdheimchesterdisease
AT amourazahir serumvascularendothelialgrowthfactorisassociatedwithcardiovascularinvolvementandresponsetotherapyinerdheimchesterdisease
AT cohenaubartfleur serumvascularendothelialgrowthfactorisassociatedwithcardiovascularinvolvementandresponsetotherapyinerdheimchesterdisease
AT harochejulien serumvascularendothelialgrowthfactorisassociatedwithcardiovascularinvolvementandresponsetotherapyinerdheimchesterdisease